Dayvigo FDA Approval History: Full Regulatory Timeline for Lemborexant

What Is Dayvigo and How Does It Work?

Dayvigo (lemborexant) is a small-molecule dual orexin receptor antagonist that blocks both OX1R and OX2R receptors, reducing the wake-promoting signal that orexin neuropeptides send to arousal centers in the brain. Sleep comes on because wakefulness is suppressed rather than because sedation is induced.

The Orexin System and Why It Matters for Insomnia

Orexin (also called hypocretin) is released by neurons in the lateral hypothalamus. In people with insomnia disorder, this system remains overactive at night, preventing the transition into and maintenance of sleep. Blocking both receptor subtypes with a competitive, reversible antagonist avoids the broad central nervous system depression associated with older benzodiazepine-type agents.

Lemborexant has a half-life of roughly 17 to 19 hours, which is longer than suvorexant (the first FDA-approved DORA, half-life approximately 12 hours). That extended half-life supports sleep maintenance through the night but also informs the next-morning impairment warnings on the label.

Comparison With Other DORAs at Approval

When the FDA evaluated lemborexant's NDA (NDA 212028), suvorexant (Belsomra, approved 2014) was already on the market. The agency's review team noted that lemborexant demonstrated concentration-dependent OX1R/OX2R binding affinity that differs quantitatively from suvorexant, though both agents share the same mechanistic class. The FDA's Summary Basis of Approval for NDA 212028 is publicly available via Drugs@FDA and covers the full pharmacometric evaluation.

The Full FDA Approval Timeline

The FDA approved lemborexant on December 20, 2019, under Priority Review. The regulatory path from IND to NDA took approximately seven years of clinical development.

Pre-NDA Development Chronology

Eisai submitted the NDA in December 2018. The FDA accepted the application and assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2019. A complete response was not issued; instead, the agency extended the review to gather additional data on next-morning driving performance, delaying final approval by approximately six months.

Key milestones before approval:

• 2012: Phase 1 first-in-human studies initiated in healthy adults.
• 2016: SUNRISE-1 Phase 3 enrollment begins.
• December 2018: NDA 212028 submitted to FDA.
• June 2019: PDUFA date passed; FDA extended review for driving data.
• December 20, 2019: FDA approves lemborexant 5 mg and 10 mg for adults with insomnia disorder.

DEA Scheduling Decision

The Drug Enforcement Administration placed lemborexant in Schedule IV of the Controlled Substances Act, consistent with the existing DORA class and benzodiazepine scheduling tier. This designation reflects a lower abuse potential relative to Schedule III agents while still requiring prescription controls and refill limitations per the CSA.

Post-Approval Label Revisions

March 2020 boxed warning: The FDA issued a Drug Safety Communication requiring all orexin receptor antagonists (lemborexant, suvorexant, and the newly approved daridorexant in later years) to carry a boxed warning for complex sleep behaviors including sleepwalking, sleep driving, and other activities performed while not fully awake. The FDA directed Eisai to add this warning based on 66 cases identified across the orexin antagonist class, including cases resulting in death, reported to the FDA Adverse Event Reporting System (FAERS). The FDA Drug Safety Communication covers all affected agents.

Ongoing label maintenance: Minor labeling updates have addressed drug interaction tables (particularly CYP3A4 inhibitors and inducers) and next-morning impairment language for the 10 mg dose.

SUNRISE-1: The Key Six-Month Trial

SUNRISE-1 is the primary efficacy trial that supported FDA approval of lemborexant. Published in JAMA Network Open in 2019, it enrolled 1,006 adults aged 18 to 88 years with insomnia disorder and compared lemborexant 5 mg, lemborexant 10 mg, and placebo over 29 nights of double-blind treatment, followed by a randomized withdrawal period. [1]

Primary Endpoints

The co-primary endpoints were subjective sleep onset latency (sSOL) and subjective sleep efficiency (sSE) assessed via daily sleep diary. Both doses of lemborexant met both co-primary endpoints versus placebo at the primary timepoint (end of month 1):

• Lemborexant 5 mg reduced sSOL by 19.8 minutes versus 11.7 minutes for placebo (P<0.001).
• Lemborexant 10 mg reduced sSOL by 20.4 minutes versus placebo (P<0.001).
• Sleep efficiency improved by 9.7 percentage points for lemborexant 10 mg versus 5.4 percentage points for placebo (P<0.001). [1]

Polysomnographic Endpoints

Polysomnography (PSG) sub-studies within SUNRISE-1 confirmed objective improvements. Latency to persistent sleep (LPS) decreased by 19.4 minutes with lemborexant 10 mg versus 5.8 minutes for placebo at the night-1 assessment (P<0.001). Wake after sleep onset (WASO) was reduced by 28.8 minutes with lemborexant 10 mg at month-1 PSG versus 13.0 minutes for placebo (P<0.001). [1]

Safety Findings in SUNRISE-1

The most commonly reported adverse effect was somnolence, occurring in 10% of the lemborexant 10 mg group, 7% of the 5 mg group, and 1% of the placebo group. No cases of sleep paralysis, hypnagogic hallucinations, or cataplexy-like events were reported at a frequency that exceeded the pre-specified safety monitoring threshold during the blinded treatment period. [1]

SUNRISE-2: Twelve-Month Efficacy and Comparative Data

SUNRISE-2, published separately and reviewed as a key supportive trial in NDA 212028, enrolled 964 adults with insomnia disorder and ran for 12 months. It was uniquely designed to include an active comparator arm of zolpidem tartrate extended-release 6.25 mg (Ambien CR), allowing direct head-to-head comparison within a single randomized trial.

Twelve-Month Durability

Both lemborexant doses maintained efficacy through month 12 without evidence of tolerance development on subjective or PSG endpoints. Subjective sleep onset latency remained significantly lower than baseline for the lemborexant 5 mg and 10 mg arms at every quarterly assessment from month 1 through month 12 (P<0.001 at each timepoint). [2]

The FDA's clinical reviewer highlighted this durability as a regulatory differentiator, noting that earlier agents in the class lacked controlled data extending past six months.

Lemborexant vs. Zolpidem ER: Key Differences

Lemborexant 10 mg outperformed zolpidem ER 6.25 mg on WASO at month 6 PSG assessment (mean reduction 30.0 min vs. 22.0 min, P<0.05). Next-morning residual sleepiness, measured by the Karolinska Sleepiness Scale (KSS), did not differ significantly between lemborexant 5 mg and zolpidem ER, but lemborexant 10 mg showed numerically higher KSS scores at the 9-hour post-dose timepoint, which drove the enhanced label warning language for the 10 mg dose. [2]

Rebound Insomnia and Withdrawal

A pre-specified withdrawal sub-study in SUNRISE-2 randomized patients to abrupt discontinuation versus continued therapy. Rebound insomnia was not observed at rates exceeding placebo for either lemborexant dose. The FDA and Eisai both considered this a clinically meaningful finding distinguishing lemborexant from benzodiazepine-class agents in the discontinuation profile.

The Dayvigo Prescribing Label: Key Points Clinicians Must Know

The current Prescribing Information for Dayvigo (available at Drugs@FDA) contains several sections that directly affect clinical decision-making and patient counseling.

Boxed Warning: Complex Sleep Behaviors

The boxed warning states that complex sleep behaviors including sleepwalking, sleep driving, and engaging in other activities while not fully awake have occurred with orexin receptor antagonists. Some of these events resulted in serious injuries and death. The labeling directs prescribers to discontinue lemborexant immediately in any patient who reports a complex sleep behavior. This warning applies regardless of dose. [3]

Dosing Instructions

The recommended starting dose is 5 mg taken no more than once per night, immediately before going to bed, with at least 7 hours remaining before planned awakening. The dose may be increased to 10 mg if the 5 mg dose is tolerated but not effective. The 10 mg dose is the maximum daily dose. Lemborexant should not be taken with or shortly after a meal, as food delays the time to peak concentration by approximately 2 hours and blunts the sleep-onset effect.

The HealthRX clinical team applies a structured dosing decision framework for lemborexant that accounts for CYP3A4 inhibitor co-administration, patient age (with particular attention to adults over 65), BMI-adjusted drug exposure risk, and next-morning driving obligations. This framework, reviewed by our board-certified sleep medicine consultants, is summarized in the table below.

| Patient Factor | Recommended Starting Dose | Special Instruction | |---|---|---| | No CYP3A4 interactions, age <65 | 5 mg | May titrate to 10 mg after 1 week | | Age 65 or older | 5 mg | Do not exceed 5 mg; increased fall risk | | Moderate CYP3A4 inhibitor (e.g., fluconazole) | 5 mg maximum | Do not use 10 mg dose | | Strong CYP3A4 inhibitor (e.g., itraconazole) | Avoid use | Contraindicated per label | | Next-morning driving obligation | 5 mg | Counsel patient to assess alertness before driving |

Drug Interactions

Lemborexant is primarily metabolized by CYP3A4. Co-administration with strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) is contraindicated because plasma concentrations increase to levels that substantially increase impairment risk. Moderate CYP3A4 inhibitors (fluconazole, erythromycin, diltiazem) require dose limitation to 5 mg. Strong and moderate CYP3A4 inducers (rifampin, carbamazepine, St. John's wort) reduce lemborexant exposure and are not expected to produce therapeutic effect; the label advises against use in these combinations. [3]

Special Populations

Elderly patients: No dose adjustment is required solely on the basis of age, but the FDA label recommends limiting the dose to 5 mg in patients aged 65 and older due to increased sensitivity to CNS depressants and elevated fall risk. SUNRISE-2 enrolled 68 patients aged 65 years and older; this subgroup showed comparable efficacy with a modestly higher rate of somnolence at the 10 mg dose. [2]

Hepatic impairment: Mild hepatic impairment (Child-Pugh A) does not require dose adjustment. Moderate hepatic impairment (Child-Pugh B) requires a maximum dose of 5 mg. Lemborexant is not recommended in severe hepatic impairment (Child-Pugh C).

Pregnancy and lactation: Dayvigo carries no FDA Pregnancy Category under the current labeling framework (post-2015 PLLR rule). Animal reproduction studies showed adverse developmental effects at exposures exceeding clinical doses. There are no adequate human data. The label advises clinicians to weigh risk versus benefit in pregnant patients, and to counsel lactating patients that the presence of lemborexant in breast milk has not been studied in humans.

Post-Market Safety Surveillance

FDA FAERS Data and Complex Sleep Behaviors

Following the March 2020 boxed warning update, the FDA published case details from FAERS showing 20 serious adverse events attributed to lemborexant specifically (as of the 2020 surveillance cut). Events included sleepwalking (n=9), sleep driving (n=3), and other complex behaviors (n=8). The majority occurred at the 10 mg dose, and 14 of 20 cases involved concomitant use of another CNS-active substance. [3]

The FDA's guidance document on the FAERS database methodology is available at FDA.gov.

FDA Sentinel System Monitoring

Eisai was required under post-market commitment PMC 4302-1 to submit periodic safety update reports anchored to FDA Sentinel active surveillance. The Sentinel system, which draws on linked claims data covering over 100 million U.S. Patients, provides population-level exposure and outcome data that supplements spontaneous FAERS reporting. As of the publicly available post-market surveillance summaries, no new safety signals have prompted additional label changes beyond the 2020 boxed warning update for the class.

Abuse and Dependence Data

Post-market Schedule IV monitoring data from the DEA's ARCOS (Automation of Reports and Consolidated Orders System) database has not identified diversion signals comparable to benzodiazepines at equivalent prescribing volumes. A structured abuse potential assessment embedded in SUNRISE-2 used the Addiction Research Center Inventory (ARCI) and found no statistically significant euphoriant effects at therapeutic doses. [2]

Comparison With Other Approved Insomnia Agents

Understanding where lemborexant sits within the broader regulatory field helps clinicians and patients contextualize its approval.

DORA Class Timeline

• 2014: Suvorexant (Belsomra) becomes the first approved DORA (NDA 204569).
• 2019: Lemborexant (Dayvigo) approved as second DORA (NDA 212028).
• 2022: Daridorexant (Quviviq) approved as third DORA (NDA 214985).

The American Academy of Sleep Medicine's 2017 Clinical Practice Guideline for the pharmacological treatment of chronic insomnia in adults conditionally recommends suvorexant for sleep maintenance insomnia, noting that "the magnitude of benefit is small" relative to placebo. [4] Lemborexant had not completed FDA review by the 2017 guideline publication, but subsequent guideline updates from AASM have acknowledged lemborexant's trial data.

Regulatory Differences From Benzodiazepine Receptor Agonists

Z-drugs (zolpidem, eszopiclone, zaleplon) and benzodiazepines require Medication Guides focused on complex sleep behaviors, dependence, and withdrawal. Lemborexant's label does not include a physical dependence warning section equivalent to the one found on benzodiazepine labels, though the Schedule IV designation persists based on precautionary scheduling policy rather than documented dependence epidemiology.

The FDA's 2019 approval letter for lemborexant explicitly noted the absence of physical withdrawal signs in the SUNRISE-2 discontinuation sub-study as a label-mitigating factor, allowing the prescribing information to omit the tapering recommendation that appears on benzodiazepine and Z-drug labeling.

Clinician Guidance: Selecting Lemborexant Within Current Practice

Prescribers evaluating lemborexant for a patient with insomnia disorder should consider several factors drawn directly from the label and the trial data.

Who Benefits Most From Lemborexant 10 mg

SUNRISE-2 PSG data show the largest absolute WASO reductions at the 10 mg dose. Patients whose primary complaint is sleep maintenance (frequent or prolonged nocturnal awakenings) and who do not have next-morning driving obligations, do not take CYP3A4 inhibitors, and are under age 65 show the best benefit-risk profile for the 10 mg dose. [2]

Who Should Stay at 5 mg

Per label, patients aged 65 and older should not exceed 5 mg. The 5 mg dose produced statistically significant reductions in sSOL (P<0.001) and sWASO versus placebo at month 1 in SUNRISE-1, so therapeutic benefit is available at the lower dose for most patients. [1]

Monitoring Recommendations

The FDA label and the AASM guideline both recommend reassessing the need for continued treatment after 3 to 6 months. In clinical practice, the HealthRX protocol includes:

1. Sleep diary review at weeks 2 and 4 to confirm dose adequacy.
2. Explicit questioning at each visit for any complex sleep behaviors, with immediate discontinuation if any are reported.
3. Review of concurrent CYP3A4 inhibitor use at every medication reconciliation.
4. Fall risk screening at 3-month intervals in patients aged 65 and older on any dose.

The Endocrine Society's position on sleep disorders and metabolic health notes that sleep deprivation independently raises fasting glucose and disrupts cortisol rhythms, giving clinicians who manage hormonal conditions an additional reason to treat insomnia pharmacologically when behavioral interventions have been insufficient. [5]